Andrographolide attenuates tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes

Molecular and Cellular Endocrinology

Volumn 332, Issue 1-2, 2011, Pages 134-139

  Jin, Lina ^a   Shi, Guojun ^a   Ning, Guang ^a,b   Li, Xiaoying ^b   Zhang, Zhiguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

3T3 L1 adipocytes; Andrographolide; Insulin resistance; NF B; TNF

Indexed keywords

ANDROGRAPHOLIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTYROSINE; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL NUCLEUS; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DITERPENES; GLUCOSE; INSULIN; INSULIN RESISTANCE; MICE; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650518919     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.10.005     Document Type: Article

References (26)

1. Abu-Ghefreh A.A., Canatan H., Ezeamuzie C.I. In vitro and in vivo anti-inflammatory effects of andrographolide. Int. Immunopharmacol. 2009, 9:313-318.
2. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
3. Chakravarti R.N., Chakravarti D. Andrographolide, the active constituent of Andrographis paniculata Nees; a preliminary communication. Ind. Med. Gaz. 1951, 86:96-97.
4. Cheung A.T., Ree D., Kolls J.K., Fuselier J., Coy D.H., Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 1998, 139:4928-4935.
5. Cseh K., Winkler G., Melczer Z., Baranyi E. The role of tumour necrosis factor (TNF)-alpha resistance in obesity and insulin resistance. Diabetologia 2000, 43:525.
6. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 1993, 268:26055-26058.
7. Heilbronn L.K., Campbell L.V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 2008, 14:1225-1230.
8. Hidalgo M.A., Romero A., Figueroa J., Cortes P., Concha I.I., Hancke J.L., Burgos R.A. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br. J. Pharmacol. 2005, 144:680-686.
9. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
10. Hotamisligil G.S. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes 1999, 107:119-125.
11. Kolb H., Mandrup-Poulsen T. An immune origin of type 2 diabetes?. Diabetologia 2005, 48:1038-1050.
12. Peraldi P., Spiegelman B.M. TNF-alpha: molecular tie between obesity and insulin resistance. Journ. Annu. Diabetol. Hotel Dieu 1997, 149-159.
13. Peraldi P., Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol. Cell. Biochem. 1998, 182:169-175.
14. Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
15. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
16. Subramanian R., Asmawi M.Z., Sadikun A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochim. Pol. 2008, 55:391-398.
17. Sulaiman M.R., Zakaria Z.A., Abdul Rahman A., Mohamad A.S., Desa M.N., Stanslas J., Moin S., Israf D.A. Antinociceptive and Antiedematogenic Activities of Andrographolide Isolated From Andrographis paniculata in Animal Models. Biol. Res. Nurs. 2010, 11:293-301.
18. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell. Biol. 2006, 7:85-96.
19. Trivedi N.P., Rawal U.M., Patel B.P. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr. Cancer Ther. 2007, 6:271-280.
20. Varma A., Padh H., Shrivastava N. Andrographolide: a new plant-derived antineoplastic entity on horizon. Evid. Based Complement. Alternat. Med. 2009, [Epub ahead of print].
21. Xia Y.F., Ye B.Q., Li Y.D., Wang J.G., He X.J., Lin X., Yao X., Ma D., Slungaard A., Hebbel R.P., Key N.S., Geng J.G. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 2004, 173:4207-4217.
22. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
23. Yu B.C., Hung C.R., Chen W.C., Cheng J.T. Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta Med. 2003, 69:1075-1079.
24. Yu B.C., Chang C.K., Su C.F., Cheng J.T. Mediation of beta-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377:529-540.
25. Zhang Z., Jiang J., Yu P., Zeng X., Larrick J.W., Wang Y. Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment. J. Transl. Med. 2009, 7:62.
26. Zhou J., Lu G.D., Ong C.S., Ong C.N., Shen H.M. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol. Cancer Ther. 2008, 7:2170-2180.